115 related articles for article (PubMed ID: 10352534)
1. [Hormone substitution therapy. Side-effects and compliance of various therapeutic regimens].
Perrone G; Barillaro F; Bazzoffi R; Capri O; Critelli C; Galoppi P; Grande S; Santoro G
Minerva Ginecol; 1999 Mar; 51(3):53-8. PubMed ID: 10352534
[TBL] [Abstract][Full Text] [Related]
2. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
3. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
4. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
[TBL] [Abstract][Full Text] [Related]
5. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
[TBL] [Abstract][Full Text] [Related]
6. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin.
Xing S; Wu Y; Liu J; Xu R; Zhang Z; Wang Y
Chin Med J (Engl); 2003 Apr; 116(4):584-7. PubMed ID: 12875727
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
8. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
9. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
Ettinger B; Pressman A; Bradley C
Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
[TBL] [Abstract][Full Text] [Related]
10. Assessment of DNA damage in postmenopausal women under hormone replacement therapy.
Ozcagli E; Sardas S; Biri A
Maturitas; 2005 Jul; 51(3):280-5. PubMed ID: 15978971
[TBL] [Abstract][Full Text] [Related]
11. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison.
Castelo-Branco C; Martínez de Osaba MJ; Fortuny A; Iglesias X; González-Merlo J
J Reprod Med; 1995 Aug; 40(8):556-60. PubMed ID: 7473451
[TBL] [Abstract][Full Text] [Related]
12. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
[TBL] [Abstract][Full Text] [Related]
13. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
Ichikawa J; Sumino H; Ichikawa S; Ozaki M
Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
[TBL] [Abstract][Full Text] [Related]
14. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.
Modena MG; Sismondi P; Mueck AO; Kuttenn F; Lignières Bd; Verhaeghe J; Foidart JM; Caufriez A; Genazzani AR;
Maturitas; 2005 Sep; 52(1):1-10. PubMed ID: 15963666
[TBL] [Abstract][Full Text] [Related]
15. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women.
Shifren JL; Desindes S; McIlwain M; Doros G; Mazer NA
Menopause; 2007; 14(6):985-94. PubMed ID: 17507833
[TBL] [Abstract][Full Text] [Related]
17. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.
Pan HA; Wang ST; Pai MC; Chen CH; Wu MH; Huang KE
J Reprod Med; 2003 May; 48(5):375-80. PubMed ID: 12815913
[TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy in postmenopausal women.
Yasui T; Uemura H; Takikawa M; Irahara M
J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
[TBL] [Abstract][Full Text] [Related]
19. Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women.
Sumino H; Ichikawa S; Takahashi T; Sakamoto H; Goto-Onozato K; Koya S; Kanda T; Nara M; Seki K; Murakami M; Kurabayashi M
Maturitas; 2006 Feb; 53(3):306-14. PubMed ID: 16040211
[TBL] [Abstract][Full Text] [Related]
20. [Effect of hormone substitution therapy on AT III in women in the climacteric].
Enzelsberger H; Heytmanek H; Kurz C; Metka M
Zentralbl Gynakol; 1991; 113(11):639-44. PubMed ID: 1656654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
